Loading…
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.3B | $90M | $59M | $192M | 11.3% | 10.4% | 7.7% |
| 2024 | $1.2B | $71M | $54M | $174M | 12.9% | 7.2% | -12.4% |
| 2023 | $1.1B | $64M | $62M | $185M | 11.2% | 38.3% | 104.4% |
| 2022 | $787M | $25M | $30M | $77M | 8.1% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 786.91 | 1,088.60 | 1,167.22 | 1,288.66 |
| Operating Revenue | - | 786.91 | 1,088.60 | 1,167.22 | 1,288.66 |
| Cost Of Revenue | - | 619.59 | 849.80 | 913.86 | 984.18 |
| Gross Profit | - | 167.32 | 238.80 | 253.36 | 304.48 |
| Operating Expense | - | 143.98 | 176.62 | 185.91 | 219.21 |
| Selling General And Administration | - | 143.98 | 176.62 | 185.91 | 219.21 |
| Total Expenses | - | 763.57 | 1,026.41 | 1,099.77 | 1,203.38 |
| Operating Income | - | 23.34 | 62.18 | 67.46 | 85.28 |
| Total Operating Income As Reported | - | 23.34 | 62.18 | 67.46 | 85.28 |
| EBITDA | - | 24.94 | 64.46 | 70.63 | 90.22 |
| Normalized EBITDA | - | 24.94 | 64.46 | 70.63 | 90.22 |
| EBIT | - | 23.34 | 62.18 | 67.46 | 85.28 |
| Interest Income | - | 1.10 | 8.51 | 15.75 | 10.15 |
| Net Interest Income | - | 1.10 | 8.51 | 15.75 | 10.15 |
| Other Non Operating Income Expenses | -0.37 | 0.29 | 5.20 | - | - |
| Other Income Expense | -0.37 | 0.29 | 5.20 | - | - |
| Interest Income Non Operating | - | 1.10 | 8.51 | 15.75 | 10.15 |
| Net Non Operating Interest Income Expense | - | 1.10 | 8.51 | 15.75 | 10.15 |
| Pretax Income | - | 24.44 | 70.69 | 83.20 | 95.43 |
| Tax Provision | - | -5.92 | 8.65 | 28.87 | 36.91 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Net Income From Continuing And Discontinued Operation | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Net Income From Continuing Operation Net Minority Interest | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Net Income | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Net Income Common Stockholders | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Net Income Including Noncontrolling Interests | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Normalized Income | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Diluted NI Availto Com Stockholders | - | 30.36 | 62.04 | 54.34 | 58.52 |
| Basic Average Shares | - | 92.20 | 95.02 | 91.48 | 85.65 |
| Diluted Average Shares | - | 99.96 | 100.67 | 95.45 | 89.86 |
| Reconciled Depreciation | - | 1.60 | 2.28 | 3.18 | 4.95 |
| Reconciled Cost Of Revenue | - | 619.59 | 849.80 | 913.86 | 984.18 |
| General And Administrative Expense | - | 98.33 | 117.13 | 121.96 | 147.09 |
| Other Gand A | - | 98.33 | 117.13 | 121.96 | 147.09 |
| Total Other Finance Cost | -0.46 | -0.81 | -3.30 | - | - |
| Selling And Marketing Expense | - | 45.66 | 59.49 | 63.95 | 72.11 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Progyny, Inc.this co. | PGNY | $2.0B | 34.11 | 3.87 | 11.3% | 21.18 |
| NovoCure Limited | NVCR | $2.1B | - | 6.12 | -40.0% | - |
| Intellia Therapeutics, Inc. | NTLA | $2.1B | - | 3.07 | -61.5% | - |
| Recursion Pharmaceuticals, Inc. | RXRX | $2.0B | -3.13 | 1.78 | -57.0% | -2.42 |
| Omnicell, Inc. | OMCL | $2.0B | 967.26 | 1.61 |
| - |
| - |
| - |
| - |
| 0.2% |
| 21.53 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B | -46.25 | 10.79 | -23.3% | -45.92 |
| Iovance Biotherapeutics, Inc. | IOVA | $2.0B | -5.00 | 2.80 | -56.0% | -5.25 |
| Ocular Therapeutix, Inc. | OCUL | $1.9B | -7.25 | 2.94 | -40.6% | -5.07 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.9B | 12.02 | 2.19 | 18.2% | 5.17 |
| Peer Median | - | -4.07 | 2.87 | -40.3% | -3.74 | |